We are live on ! Find out more
UNCY icon

Unicycive Therapeutics

29 hedge funds and large institutions have $34.5M invested in Unicycive Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

0.17% less ownership

Funds ownership: 5.94%5.77% (-0.17%)

3% less funds holding

Funds holding: 3029 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

30% less capital invested

Capital invested by funds: $49M → $34.5M (-$14.6M)

Holders
29
Holders Change
-1
Holders Change %
-3.33%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
9
Reduced
8
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
26
Bank of America
North Carolina
$246 +$12 +2 +5%
JP Morgan Chase
27
JP Morgan Chase
New York
$106 -$12 -2 -10%
BWL
28
Bogart Wealth LLC
Virginia
$34
SS
29
SBI Securities
Japan
$14 -$12 -2 -40%
ACM
30
Altium Capital Management
New York
-$1.17M -147,300 Closed
HAIM
31
Hunter Associates Investment Management
Pennsylvania
-$12K -1,500 Closed
TRCT
32
Tower Research Capital (TRC)
New York
-$8.64K -1,089 Closed
FI
33
FWG Investments
Kentucky
-$8.12K -1,022 Closed
SWA
34
SOA Wealth Advisors
New York
-$794 -100 Closed
Citigroup
35
Citigroup
New York
-$466 -59 Closed

UNCY Hedge Fund Activity: Q1 2025 in Review

29 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2025, worth a combined $34.5M — down 30% from $49M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of UNCY and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 9 added.

The largest buyer was Vivo Capital, adding an estimated $854K. The largest seller was Altium Capital Management, exiting entirely with an estimated $1.17M sold.

  • 29 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2025, down from 30 in Q4 2024.
  • Funds reported $34.5M of Unicycive Therapeutics stock for Q1 2025, down 30% quarter-over-quarter.
  • 5 funds opened new Unicycive Therapeutics positions in Q1 2025 and 6 closed out, a net change of -1 holder.
  • The largest Unicycive Therapeutics buyer in Q1 2025 was Vivo Capital, an estimated $854K added.
  • The largest Unicycive Therapeutics seller in Q1 2025 was Altium Capital Management, an estimated $1.17M sold.

Based on aggregated 13F filings for Q1 2025.